Carboplatin plus etoposide

images carboplatin plus etoposide

Thereafter, participants received maintenance Cycle 5 onward placebo on Day 1 of every day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor. Study record managers: refer to the Data Element Definitions if submitting registration or results information. Find the essential information, user-friendly publications and resources presenting recent developments on these treatments. While this approach may be appropriate for many cancer types, SCLC may be particularly vulnerable to this treatment strategy. Please refer to this study by its ClinicalTrials. Results First Posted : July 2, Patients with known Gilbert disease who have serum bilirubin level 3 ULN may be enrolled. Accepts Healthy Volunteers:.

  • Carboplatin and etoposide Macmillan Cancer Support
  • Carboplatin plus etoposide regimen in advanced breast cancer. A phase II study.

  • Carboplatin and etoposide Macmillan Cancer Support

    Carboplatin plus etoposide for extensive stage small-cell lung cancer: an experience with AUC 6 doses of carboplatin. Yilmaz U(1), Polat G, Anar C, Halilcolar H. Eur J Gynaecol Oncol. ;18(3) Carboplatin plus etoposide regimen in advanced breast cancer. A phase II study.

    Deltetto F(1), Durando A, Camanni M. Carboplatin and etoposide chemotherapy is used to treat small cell cancers, including small cell lung cancer and small cell bladder cancer.
    Thereafter, participants received maintenance Cycle 5 onward atezolizumab mg on Day 1 of every day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.

    Actual Study Completion Date :. Accepts Healthy Volunteers:. Abstract Background The current standard first-line treatment for the majority of patients pts with extensive-stage small cell lung cancer ES-SCLC is platinum-based chemotherapy with etoposide.

    Sandler 5A.

    images carboplatin plus etoposide
    Carboplatin plus etoposide
    More Information.

    Video: Carboplatin plus etoposide Carboplatin and Etoposide Lung Cancer Clinical Trial

    Study Type :. Waterkamp 5S. More Information.

    images carboplatin plus etoposide

    This study will be conducted at approximately ten sites in the United States. Practice Tools ESMO has developed a set of organ-specific tools designed to assist oncologists in their daily practice.

    images carboplatin plus etoposide

    Department of Health and Human Services.

    eBackground: Unresectable/metastatic adrenal cortical carcinoma (ACC) is a rare malignancy with limited treatment options. The current. A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC ).

    Official Title: An Open Label, Randomized Phase I/II Trial of Carboplatin Plus Etoposide With ot Without MPDLA in Untreated Extensive Stage Small Cell .
    Waterkamp 5S.

    Epub Aug 2. Liu, S. Rare Cancers Resources for Patients. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Find the essential information, user-friendly publications and resources presenting recent developments on these treatments.

    images carboplatin plus etoposide
    OBAT GONDONGAN PADA ANAKINRA
    Epub Apr 2.

    Sign-up to receive the OncologyPRO alert every 2 weeks. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Save this study. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

    Abstract Background The current standard first-line treatment for the majority of patients pts with extensive-stage small cell lung cancer ES-SCLC is platinum-based chemotherapy with etoposide.

    Carboplatin AUC IV on day 1 plus etoposide mg/m2 IV on days every 28d (see also the Carboplatin AUC Dose Calculation.

    Reason for Update: Etoposide concentration limits. Version: Approved by Consultant: Supersedes: All other versions. Date: 14/08/ Prepared. Carboplatin plus etoposide — (table 1).

    To continue reading this article, you must log in. For more information or to purchase a personal.
    Arms and Interventions. Phase 3. Inclusion Criteria: Signed Informed Consent Form ICF Ability and willingness to comply with the requirements of the study protocol Age 18 years or older Histological or cytological diagnosis of ES-SCLC Note: Extensive-stage disease is defined as disease beyond the ipsilateral hemithorax, mediastinum and ipsilateral supraclavicular area and including malignant pleural or pericardial effusion or hematogenous metastases Patients with mixed histology SCLC and NSCLC are permitted Representative tumor specimens in paraffin blocks preferred or at least 10 unstained slides, with an associated pathology report, requested at any time prior to study entry.

    The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Find the essential information, user-friendly publications and resources presenting recent developments on these treatments.

    Read our disclaimer for details.

    images carboplatin plus etoposide
    PENTATEUCH LAW CODES IN OHIO
    Positive test result for human immunodeficiency virus HIV Active hepatitis B or hepatitis C Severe infections at the time of randomization Significant cardiovascular disease Prior treatment with cluster of differentiation CD agonists or immune checkpoint blockade therapies, anti-programmed death-1 PD-1and anti-PD-L1 therapeutic antibody History of severe or known hypersensitivity to chimeric or humanized antibodies or fusion proteins or any component of atezolizumab formulation.

    Carboplatin plus etoposide regimen in advanced breast cancer. A phase II study.

    Talk with your doctor and family members or friends about deciding to join a study. Essentials for Clinicians A simplified yet comprehensive overview on oncological malignancies, their biology, diagnosis, staging, treatment and follow-up, which are necessary for basic patient treatment. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Thereafter, participants received maintenance Cycle 5 onward atezolizumab mg on Day 1 of every day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.

    Please refer to this study by its ClinicalTrials. Treatment can be continued until persistent radiographic PD or symptomatic deterioration.

    4 thoughts on “Carboplatin plus etoposide